The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Six months compared with 12 months of capecitabine as adjuvant chemotherapy for stage III (Dukes' C) colon cancer: Rationale for the open-label randomized phase III study, JFMC37-0801.
Takao Takahashi
Disclosure not yet available
Kazuhiro Yoshida
Disclosure not yet available
Chikuma Hamada
Disclosure not yet available
Junichi Sakamoto
Disclosure not yet available
Taroh Satoh
Disclosure not yet available
Sotaro Sadahiro
Disclosure not yet available
Hideyuki Mishima
Disclosure not yet available
Masahiko Watanabe
Disclosure not yet available
Kenichi Sugihara
Disclosure not yet available
Naohiro Tomita
Disclosure not yet available